211 related articles for article (PubMed ID: 25777075)
41. [Prognostic marker profiles for risk of distant metastases in colorectal cancer].
Neumann J; Reu S; Kirchner T
Pathologe; 2012 Feb; 33(1):39-44. PubMed ID: 22293788
[TBL] [Abstract][Full Text] [Related]
42. Molecular testing for microsatellite instability and DNA mismatch repair defects in hereditary and sporadic colorectal cancers--ready for prime time?
Søreide K
Tumour Biol; 2007; 28(5):290-300. PubMed ID: 17962726
[TBL] [Abstract][Full Text] [Related]
43. Microsatellite instability and B-type Raf proto-oncogene mutation in colorectal cancer: Clinicopathological characteristics and effects on survival.
Batur S; Vuralli Bakkaloglu D; Kepil N; Erdamar S
Bosn J Basic Med Sci; 2016 Nov; 16(4):254-260. PubMed ID: 27131021
[TBL] [Abstract][Full Text] [Related]
44. Increased cancer predisposition in family members of colorectal cancer patients harboring the p.V600E BRAF mutation: a population-based study.
Wish TA; Hyde AJ; Parfrey PS; Green JS; Younghusband HB; Simms MI; Fontaine DG; Dicks EL; Stuckless SN; Gallinger S; McLaughlin JR; Woods MO; Green RC
Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1831-9. PubMed ID: 20570909
[TBL] [Abstract][Full Text] [Related]
45. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
[TBL] [Abstract][Full Text] [Related]
46. Role of the BRAF mutations in the microsatellite instability genetic pathway in sporadic colorectal cancer.
Maestro ML; Vidaurreta M; Sanz-Casla MT; Rafael S; Veganzones S; Martínez A; Aguilera C; Herranz MD; Cerdán J; Arroyo M
Ann Surg Oncol; 2007 Mar; 14(3):1229-36. PubMed ID: 17195912
[TBL] [Abstract][Full Text] [Related]
47. [Correlation between microsatellite instability and morphology in colorectal cancer].
Szentirmay Z; Gallai M; Serester O; Szoke J; Tóth E
Magy Onkol; 2010 Jun; 54(2):169-78. PubMed ID: 20576594
[TBL] [Abstract][Full Text] [Related]
48. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
[TBL] [Abstract][Full Text] [Related]
49. BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression.
Landau MS; Kuan SF; Chiosea S; Pai RK
Hum Pathol; 2014 Aug; 45(8):1704-12. PubMed ID: 24908142
[TBL] [Abstract][Full Text] [Related]
50. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.
Zlobec I; Bihl MP; Foerster A; Rufle A; Lugli A
Histopathology; 2012 Nov; 61(5):777-87. PubMed ID: 22803799
[TBL] [Abstract][Full Text] [Related]
51. Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability.
Lanza G; Gafà R; Maestri I; Santini A; Matteuzzi M; Cavazzini L
Mod Pathol; 2002 Jul; 15(7):741-9. PubMed ID: 12118112
[TBL] [Abstract][Full Text] [Related]
52. Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome.
van Lier MG; Leenen CH; Wagner A; Ramsoekh D; Dubbink HJ; van den Ouweland AM; Westenend PJ; de Graaf EJ; Wolters LM; Vrijland WW; Kuipers EJ; van Leerdam ME; Steyerberg EW; Dinjens WN;
J Pathol; 2012 Apr; 226(5):764-74. PubMed ID: 22081473
[TBL] [Abstract][Full Text] [Related]
53. Subtyping of microsatellite instability-high colorectal cancer.
Hu W; Yang Y; Qi L; Chen J; Ge W; Zheng S
Cell Commun Signal; 2019 Jul; 17(1):79. PubMed ID: 31331345
[TBL] [Abstract][Full Text] [Related]
54. The utility of diagnostic biopsy specimens for predictive molecular testing in colorectal cancer.
Fadhil W; Ibrahem S; Seth R; AbuAli G; Ragunath K; Kaye P; Ilyas M
Histopathology; 2012 Dec; 61(6):1117-24. PubMed ID: 22882224
[TBL] [Abstract][Full Text] [Related]
55. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
56. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
Heinemann V; Stintzing S; Kirchner T; Boeck S; Jung A
Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
[TBL] [Abstract][Full Text] [Related]
57. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
[TBL] [Abstract][Full Text] [Related]
58. Fusobacterium nucleatum load in MSI colorectal cancer subtypes.
Ono T; Yamaguchi T; Takao M; Kojika E; Iijima T; Horiguchi SI
Int J Clin Oncol; 2022 Oct; 27(10):1580-1588. PubMed ID: 35859218
[TBL] [Abstract][Full Text] [Related]
59. Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation.
Chung C
J Oncol Pharm Pract; 2022 Jun; 28(4):850-869. PubMed ID: 33832365
[TBL] [Abstract][Full Text] [Related]
60. BRAF mutation testing in colorectal cancer.
Sharma SG; Gulley ML
Arch Pathol Lab Med; 2010 Aug; 134(8):1225-8. PubMed ID: 20670148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
